ArticleFrontiers in oncology2025
Development and validation of nomograms for predicting grade ≥3 diarrhea and neutropenia after abemaciclib combined with endocrine therapy for breast cancer: a multicenter retrospective real-world study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to investigate the risk factors associated with grade ≥3 diarrhea and neutropenia, which are the most common adverse events (AEs) leading to discontinuation and dose reduction in patients with hormone receptor-positive (HR+)/human epidermal growth factor 2-negative (HER2-) breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitor abemaciclib combined with endocrine therapy (ET). Subsequently, two prediction nomograms were developed to serve as a foundation for enhancing the management of patients' side effects and improving treatment quality. Methods: A retrospective cohort analysis was conducted to explore the clinical characteristics and treatment variables of breast cancer patients treated with abemaciclib combined with ET in Yunnan Cancer Hospital from December 2021 to December 2022. Logistic regression was used to determine the risk factors for the occurrence of grade ≥3 diarrhea and neutropenia, and two kinds of nomograms were established. An external validation group of patients from three additional centers was used to validate the constructed nomograms. The area under the receiver operating characteristic (ROC) curve (AUC), calibration curve, and decision curve analysis (DCA) were used to assess the predictive performance and clinical applicability of the two nomograms. Results: A total of 497 patients were included, including 403 in the modeling group and 94 in the external validation group. The results of the multifactorial analysis revealed that age ≥70 years, Eastern Cooperative Oncology Group (ECOG) score ≥1, and underlying gastrointestinal diseases were independent risk factors for grade ≥3 diarrhea. ECOG score ≥1, radiotherapy in the same period/within 1 month, and neutrophils ≤2.0×10 Conclusion: We identified risk factors for grade ≥3 diarrhea and neutropenia in patients treated with abemaciclib combined with ET, and established a risk prediction nomogram, providing a scientific basis for safety assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.